4,060 Shares in Danaher Corporation (NYSE:DHR) Bought by Trivant Custom Portfolio Group LLC

Trivant Custom Portfolio Group LLC bought a new position in Danaher Corporation (NYSE:DHR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,060 shares of the conglomerate's stock, valued at approximately $832,000.

Several other institutional investors also recently bought and sold shares of DHR. Fortis Capital Advisors LLC lifted its position in Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after purchasing an additional 50 shares during the period. Fayez Sarofim & Co raised its stake in shares of Danaher by 0.6% in the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after buying an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC raised its stake in shares of Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after buying an additional 50 shares in the last quarter. Perennial Investment Advisors LLC lifted its holdings in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after buying an additional 51 shares during the period. Finally, Sound View Wealth Advisors Group LLC boosted its stake in Danaher by 3.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after buying an additional 52 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 0.7%

Shares of NYSE:DHR traded down $1.39 during trading on Thursday, reaching $194.36. 3,236,239 shares of the company traded hands, compared to its average volume of 3,488,121. The firm has a fifty day simple moving average of $193.46 and a 200 day simple moving average of $210.32. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The firm has a market cap of $139.10 billion, a P/E ratio of 37.74, a price-to-earnings-growth ratio of 2.75 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.66%. Danaher's payout ratio is 24.85%.

Insider Buying and Selling

In related news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on DHR. Robert W. Baird cut their price target on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Jefferies Financial Group cut their target price on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research note on Tuesday, April 22nd. Wall Street Zen cut shares of Danaher from a "buy" rating to a "hold" rating in a report on Monday, June 9th. JPMorgan Chase & Co. dropped their price target on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $248.17.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.